
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc is positioned for a positive outlook due to anticipated faster growth in the spine market, alongside increased sales from its Enabling Technologies segment, which could lead to improved profit margins. The company is expecting organic growth to enhance revenue guidance, notably with a strong performance in the US Spine market and an impressive 10% growth in Nevro sales in the fourth quarter. Furthermore, as Globus Medical integrates NuVasive and advances in manufacturing, significant gross margin expansion is projected, stabilizing EBITDA margins around 34-35% by 2026, which supports a strong financial foundation for the company.
Bears say
The analysis highlights several significant risks contributing to a negative outlook for Globus Medical's stock. Key concerns include potential sluggish growth in the spine market, revenue disruption related to ongoing mergers, and underperformance in Enabling Technologies sales, all of which could lead to a decline in operating margins and overall financial performance. Additionally, the company faces competitive pressures from newly focused spine franchises and risks associated with delayed market introductions for key products, further complicating its growth trajectory.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares